HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD.

AbstractBACKGROUND:
Osteoprotegerin (OPG), a potent inhibitor of osteoclastogenesis, decreases bone resorption and has protective effects on bone mineral density (BMD). Recently we have shown that the adipose-tissue derived OPG relates to BMD in patients with chronic obstructive pulmonary disease (COPD), a condition associated with increased risk of osteoporosis.
OBJECTIVE:
Here we aimed to investigate the potential of circulatory OPG to reflect hip BMD in patients with COPD.
PATIENTS AND METHODS:
In 56 subjects with COPD [age, 61.7 ± 6.7 years; forced expiratory volume in 1 s (FEV1), 53.6 ± 19.2% predicted], total femur BMD was assessed by dual energy X-ray absorptiometry, serum OPG and β-crosslaps, a marker of increased bone resorption, by commercially available assays.
RESULTS:
From patients with normal hip BMD (n = 32, T-score 0.1 ± 0.8) to those with osteopenia (n = 14, T-score -1.6 ± 0.4) and osteoporosis (n = 10, T-score -3.4 ± 0.7) serum OPG levels significantly increased (6.6 ± 1.8 versus 7.2 ± 2.9 and versus 8.6 ± 1.5 pmol/l, p = 0.036). In addition, hip T-scores were directly related to FEV1, and inversely to β-crosslaps (R = 0.40, p = 0.002; R = 0.38, p = 0.01, respectively). In multivariate analysis, OPG independently predicted hip T-scores after adjustments for age, gender, FEV1, and β-crosslaps (p = 0.011, adjusted R(2) = 0.354). Area under receiver operator curve for OPG as a discriminator of osteoporosis was 0.787 (95% CI, 0.653-0.921) (p = 0.005).
CONCLUSIONS:
Present results suggest that osteoporosis of the hip is associated with increased circulatory levels of OPG in patients with COPD. OPG might serve as a biomarker of this COPD-related comorbidity.
AuthorsPavol Pobeha, Darina Petrasova, Ruzena Tkacova, Pavol Joppa
JournalRespiratory medicine (Respir Med) Vol. 108 Issue 4 Pg. 621-7 (Apr 2014) ISSN: 1532-3064 [Electronic] England
PMID24424018 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Biomarkers
  • Osteoprotegerin
  • RANK Ligand
  • TNFRSF11B protein, human
  • TNFSF11 protein, human
Topics
  • Aged
  • Biomarkers (blood)
  • Body Composition (physiology)
  • Bone Density (physiology)
  • Cross-Sectional Studies
  • Female
  • Forced Expiratory Volume (physiology)
  • Hip Joint (physiopathology)
  • Humans
  • Lumbar Vertebrae (physiopathology)
  • Male
  • Middle Aged
  • Osteoporosis (diagnosis, etiology, physiopathology)
  • Osteoprotegerin (blood)
  • Pulmonary Disease, Chronic Obstructive (complications, physiopathology)
  • RANK Ligand (blood)
  • Respiratory Function Tests (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: